A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A phase 1/2 trial of Rilvegostomig in melanoma and non-small-cell lung cancer, run by AstraZeneca, now recruiting.
Overview
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07115043 by AstraZeneca, with 120 participants planned, started 2025-07-29 and due to reach its primary completion in 2029-10-02. Interventions recorded: AZD6750, rilvegostomig. Conditions listed: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer.
- TrialPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer.
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Renal cell carcinoma, Melanoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Rilvegostomig, AstraZeneca, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Shares Renal cell carcinoma, Melanoma, Small-cell lung cancer, Non-small-cell lung cancer.